The future endocrine patient. Reflections on the future of clinical endocrinology

European Journal of Endocrinology

Volumn 149, Issue 3, 2003, Pages 169-175

  Lamberts, S W J ^c   Romijn, J A ^a   Wiersinga, W M ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM; CORTICOTROPIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; FOLLITROPIN; GROWTH HORMONE; HORMONE DERIVATIVE; HYDROCORTISONE; INSULIN; LEVOTHYROXINE; LUTEINIZING HORMONE; SEX HORMONE; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR; TESTOSTERONE; THYROTROPIN; THYROXINE; TUBERCULOSTATIC AGENT; VITAMIN D;

AGING; APPETITE; ARTICLE; BODY COMPOSITION; CHRONIC DISEASE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; ENDOCRINE DISEASE; ENDOCRINOLOGY; FATIGUE; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; HYPOTHYROIDISM; INCOME; INFERTILITY; LIFESTYLE; MEDICAL RESEARCH; MEDICAL SOCIETY; MULTIPLE PREGNANCY; PRIORITY JOURNAL; REPRODUCTION; SEXUALITY; SHORT STATURE; TUBERCULOSIS; WESTERN EUROPE;

ENDOCRINE SYSTEM DISEASES; ENDOCRINOLOGY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE;

EID: 0141516556     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1490169     Document Type: Article

References (49)

1. Wass JA. The future of endocrinology in Europe - a view from across La Manche on connection to the mainland. European Journal of Endocrinology 1996 134 393-394.
2. Milgrom E. Endocrinology in France: present status and future. European Journal of Endocrinology 1996 134 137-138.
3. Sanchez-Franco F. Forecasting the future of endocrinology in Europe. European Journal of Endocrinology 1996 134 139-142.
4. Wuttke W. German Endocrine Society. European Journal of Endocrinology 1996 134 261-262.
5. Burger AG & Philippe J. Endocrinology in Switzerland: hopes and concerns. European Journal of Endocrinology 1997 136 265-266.
6. Hansson V, Skalhegg BS & Tasken K. Is basic endocrinology disappearing? European Journal of Endocrinology 1996 134 7-8.
7. Bouillon R. The future of endocrinology and the endocrinologist of the future. Hormone Research 2001 56 98-105.
8. Joslin EP & Wilson WJ. Lessons for future treatment. British Medical Journal 1950 1 1293-1296.
9. Joslin E. A half-century's experience in diabetes mellitus. British Medical Journal 1950 1 1095-1098.
10. Feudtner C. A disease in motion: diabetes history and the new paradigm of transmuted disease. Perspectives in Biology and Medicine 1996 39 158-170.
11. Baan CA, Nusselder WJ, Barendregt JJ, Ruwaard D, Bonneux L & Feskens EJ. The burden of mortality of diabetes mellitus in The Netherlands. Epidemiology 1999 10 184-187.
12. Huang ES, Meigs JB & Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. American Journal of Medicine 2001 111 633-642.
13. Wilson JD. Prospects for research for disorders of the endocrine system. Journal of the American Medical Association 2001 285 624-627.
14. Thomas L. On the science and technology of medicine. Daedalus 1977 35-46.
15. Carr D, McLeod DT, Parry G & Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clinical Endocrinology 1988 28 325-333.
16. Bunevicius R, Kazanavicius G, Zalinkevicius R & Prange AJ Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. New England Journal of Medicine 1999 340 424-429.
17. Weetman AP. Thyroxine treatment in biochemically euthyroid but clinically hypothyroid individuals. Clinical Endocrinology 2002 57 25-27.
18. Saravanan P, Chan WF, Roberts N, Vedhara K, Greenwood R & Dayan CM. Psychological well-being in patients on 'adequate' doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clinical Endocrinology 2002 57 577-585.
19. Oelkers W, Diederich S & Bahr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. Journal of Clinical Endocrinology and Metabolism 1992 75 259-264.
20. Thompson DG, Mason AS & Goodwin FJ. Mineralocorticoid replacement in Addison's disease. Clinical Endocrinology 1979 10 499-506.
21. Hunt PJ, Gurnell EM, Huppert EA, Richards C, Prevost AT, Wass JA et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double-blind trial. Journal of Clinical Endocrinology and Metabolism 2000 85 4650-4656.
22. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V et al. Testosterone replacement therapy improves mood in hypogonadal men - a clinical research center study. Journal of Clinical Endocrinology and Metabolism 1996 81 3578-3583.
23. Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. European Journal of Endocrinology 2002 146 215-222.
24. Andersen S, Pedersen KM, Bruun NH & Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. Journal of Clinical Endocrinology and Metabolism 2002 87 1068-1072.
25. Just how tainted has medicine become? Lancet 2002 359 1167.
26. Huizenga NA, Koper JW, de Lange P, Pols HA, Stolk RP, Grobbee DE et al. Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. Journal of Clinical Endocrinology and Metabolism 1998 83 47-54.
27. Huizenga NA, Koper JW, De Lange P, Pols HA, Stolk RP, Burger H et al. A polymorphism in the glucocorticoid receptor gene may be associated with an increased sensitivity to glucocorticoids in vivo. Journal of Clinical Endocrinology and Metabolism 1998 83 144-151.
28. van Rossum EF, Koper JW, Huizenga NA, Uitterlinden AG, Janssen JA, Brinkmann AO et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 2002 51 128-134.
29. Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001 50 637-642.
30. Owen K & Hattersley AT. Maturity-onset diabetes of the young: from clinical description to molecular genetic characterization. Best Practice and Research Clinical Endocrinology and Metabolism 2001 15 309-323.
31. Fajans SS, Bell GI & Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. New England Journal of Medicine 2001 345 971-980.
32. Beutler E, Felitti VJ, Koziol JA, Ho NJ & Gelbart T. Penetrance of 845G → A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002 359 211-218.
33. Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH & Kastelein JJ. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. British Medical Journal 2001 322 1019-1023.
34. Sijbrands EJ, Westendorp RG, Paola Lombardi M, Havekes LM, Frants RR, Kastelein JJ et al. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis 2000 149 421-425.
35. Schuster H & Luft FC. Clinical criteria versus DNA diagnosis in heterozygous familial hypercholesterolemia: is molecular diagnosis superior to clinical diagnosis? Arteriosclerosis Thrombosis and Vascular Biology 1998 18 331-332.
36. Jansen AC, van Wissen S, Defesche JC & Kastelein JJ. Phenotypic variability in familial hypercholesterolaemia: an update. Current Opinion in Lipidology 2002 13 165-171.
37. Willett WC. Balancing life-style and generates research for disease prevention. Science 2002 296 695-698.
38. Rees J. Complex disease and the new clinical sciences. Science 2002 296 698-700.
39. Strohman R. Manouvering in the complex path from genotype to phenotype. Science 2002 296 701-703.
40. Collins FS. Shattuck Lecture - Medical and societal consequences of the Human Genome Project. New England Journal of Medicine 1999 341 28-37.
41. Smith R. In search of 'non-disease'. British Medical Journal 2002 324 883-885.
42. Moynihan R & Smith R. Too much medicine? British Medical Journal 2002 324 859-860.
43. Tattersall RL. The expert patient: a new approach to chronic disease management for the twenty-first century. Clinical Medicine 2002 2 227-229.
44. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Journal of the American Medical Association 1998 280 2077-2082.
45. Lamberts SW, van den Beld AW & van der Lely AJ. The endocrinology of aging. Science 1997 278 419-424.
46. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 2002 288 321-333.
47. Brennan MD, Miner KM & Rizza RA. Profiles of the endocrine clinic: the Mayo Clinic. Journal of Clinical Endocrinology and Metabolism 1998 83 3427-3434.
48. Greenfield S, Kaplan SH, Kahn R, Ninomiya J & Griffith JL. Profiling care provided by different groups of physicians: effects of patient case-mix (bias) and physician-level clustering on quality assessment results. Annals of Internal Medicine 2002 136 111-121.
49. Eisenberg JM. Measuring quality: are we ready to compare the quality of care among physician groups? Annals in Internal Medicine 2002 136 153-154.